Background: A range of symptoms can be present in persons at risk of rheumatoid arthritis (RA). However, information on the nature, location, timing, severity and predictive value of these symptoms is largely lacking. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire has been developed with support from EULAR, informed by data from a qualitative study 1 and with input from patient research partners. Objectives: To test the psychometric properties of the SPARRA questionnaire in an international group of arthralgia patients at risk of RA and to quantify these symptoms. Methods: The SPARRA questionnaire contains questions about presence, severity, impact and location of 13 symptoms. 240 individuals (69% rheumatoid factor and/or ACPA positive, 23% seronegative with clinically suspect arthralgia and 8% first degree family members of patients with RA) completed the questionnaire in the Netherlands (N=125), United Kingdom (N=70), Sweden (N=15), Austria (N=11) and Switzerland (N=19). Individuals had no history or presence of clinically diagnosed arthritis at the time of first physical examination. Reliability (test-retest) and validity (face, content and construct validity) were tested.
Results: Face validity was tested by a group of experts on the at-risk phase of RA and feedback on the questionnaire was asked and received from 30 arthralgia patients, leading to only minor comments. The test-retest within 7-14 days (N=51) showed moderate to good agreement (kappa mean 0.565, range 0.309-1; agreement mean 71%, range 59-100%). The content validity was high, in line with the fact that the items were derived from a qualitative study in seropositive arthralgia patients. In contrast, the construct validity (relation to visual analog scale scores (VAS) for pain and well-being) was low (R-square 0.040-0.199), suggesting that the questions measure different elements in different time frames and grasp symptom content not captured with regular VAS pain/well-being. Most symptoms were present in a high percentage of individuals, with pain, stiffness and fatigue as the most common ones. When a symptom was present, it was usually experienced as moderate to severe, and with moderate impact. ACPA positive individuals reported lower presence of symptoms then ACPA negative individuals (mean 47% for ACPA-positive (N=118), 41% for only RF positives (N=53) and 59% in seronegative individuals (N=69)), but functional impact was higher in ACPA positive individuals (51%, versus 42% in seronegatives, NS). Note that the inclusion criteria for the seronegative individuals was presence of symptoms.
Conclusions:
This study provides evidence of good psychometric properties of the SPARRA questionnaire, except for low construct validity. This means the questionnaire adds information to currently available clinical measures in persons at risk of RA. Future studies are needed to evaluate whether SPARRA data can help to improve the prediction of RA. Background: Several risk loci for Rheumatoid Arthritis (RA) have been identified by Genome Wide Association Studies (GWAS), but they do not include Allograft Inflammatory Factor 1 (AIF1). Nevertheless, a few studies have shown that AIF1 rs2269475 (C/T) is associated with RA 1,2 . Objectives: We propose 1) To examine associations in French Caucasian patients with RA, of the seven most described AIF1 SNPs; 2) To study their linkage disequilibrium with HLA-DRB1 alleles; 3) To evaluate whether AIF1 single nucleotide polymorphisms (SNPs) could predict first line treatment responses in RA. Methods: We amplified the AIF1 gene region containing the 7 SNPs and sequenced PCR products on a total of 469 individuals, including 95 AntiCitrullinated Protein Antibody (ACPA) positive RA patients, 146, patients with scleroderma, 132 healthy controls and 96 additional healthy controls selected from a large database of volunteer bone marrow donors (VBMD) for carrying at least one RA-associated allele. Patients and controls were HLA-DRB1 genotyped. Patients with RA were divided into 2 groups, a first group called "non responders" was defined as patients who did not respond to first-line methotrexate (MTX) combined with Etanercept and a second group called "good responders" was defined as patients who did respond to methotrexate combined with Etanercept. Results: Two SNPs were associated with RA: rs4711274 (G/A) and rs2269475 (C/T). The frequency of minor allele carriers was respectively 37% (A) and 36% (T) in patients with RA versus 18% among controls (p=0.0014 and p=0.001). Furthermore, patients with RA-associated HLA-DRB1 alleles carried more often minor alleles for both SNPs (p=0.0005). Preliminary clinical data show that 56% of non-responders (N=16) carried the minor alleles of both rs4711274 and rs2269475 compared to only 21% of good responders (N=24, p=0.02). Conclusions: AIF is an inflammation-responsive protein encoded within the HLA class III region on chromosome 6 (6p21.3). As already described in British and Polish Caucasians, we found a significant AIF1 Rs2269475 association with RA. We also found an association with Rs4711274 in linkage disequilibrium with the former. The increased frequency of minor AIF1 alleles in RA was not associated with a particular HLA-DRB1 allele, but to any HLA-DRB1 allele carrying the shared epitope. Finally, patients who failed to respond to Etanercept and MTX carried more often minor alleles of the 2 described AIF1 SNPs. Further analysis on a larger groups of patients is required to confirm whether AIF1 SNPs can predict response to therapy with Etanercept and Methotrexate.
POLYMORPHISMS RS4711274 (G/A) AND RS2269475 (C/T) MAY PREDICT ETANERCEPT PLUS METHOTREXATE RESPONSE IN FRENCH CAUCASIAN PATIENTS WITH RHEUMATOID ARTHRITIS
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